These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10729201)

  • 1. DNA as a possible target for antitumor ruthenium(III) complexes.
    Gallori E; Vettori C; Alessio E; Vilchez FG; Vilaplana R; Orioli P; Casini A; Messori L
    Arch Biochem Biophys; 2000 Apr; 376(1):156-62. PubMed ID: 10729201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
    Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
    Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
    Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
    Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, interaction with double-helical DNA and biological activity of the water soluble complex cis-dichloro-1,2-propylenediamine-N,N,N',N'-tetraacetato ruthenium (III) (RAP).
    Vilaplana RA; Delmani F; Manteca C; Torreblanca J; Moreno J; García-Herdugo G; González-Vílchez F
    J Inorg Biochem; 2006 Nov; 100(11):1834-41. PubMed ID: 16959320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.
    Gopal YN; Jayaraju D; Kondapi AK
    Biochemistry; 1999 Apr; 38(14):4382-8. PubMed ID: 10194357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
    Ravera M; Baracco S; Cassino C; Zanello P; Osella D
    Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
    Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
    J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
    Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
    Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
    Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
    Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
    Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
    Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA conformational changes and cleavage by ruthenium(II) nitrofurylsemicarbazone complexes.
    Otero L; Smircich P; Vieites M; Ciganda M; Severino PC; Terenzi H; Cerecetto H; Gambino D; Garat B
    J Inorg Biochem; 2007 Jan; 101(1):74-9. PubMed ID: 17027974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.
    Messori L; Orioli P; Vullo D; Alessio E; Iengo E
    Eur J Biochem; 2000 Feb; 267(4):1206-13. PubMed ID: 10672032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin.
    Calamai P; Carotti S; Guerri A; Mazzei T; Messori L; Mini E; Orioli P; Speroni GP
    Anticancer Drug Des; 1998 Jan; 13(1):67-80. PubMed ID: 9474243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
    Groessl M; Zava O; Dyson PJ
    Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.